Charles River Laboratories International (CRL) News Today

Charles River Laboratories International, Inc. (NYSE: CRL) shares increased after the company’s Investor Day reinforced its near-term outlook and introduced ambitious long-term growth targets. The move reflects improved investor confidence, although some analysts believe the positive news is already reflected in the valuation.

• Positive Sentiment: Charles River reaffirmed its fiscal 2026 revenue outlook of approximately $3.9 billion and raised its EPS guidance to $11.45, modestly above the analyst consensus of $11.33. Charles River sets 2030 targets, lifts 2026 earnings outlook
• Positive Sentiment: At Investor Day, management outlined 2030 growth objectives that imply stronger revenue and earnings expansion over the long term. The targets, together with the reaffirmed 2026 outlook, prompted a sharp rise in the stock as investors responded favorably to the company’s strategy and earnings potential. Charles River Stock Rises After Unveiling 2030 Growth Targets
• Positive Sentiment: Robert W. Baird raised its price target from $291 to $334 and maintained an “outperform” rating, citing additional upside following the Investor Day update. Baird price-target update
• Neutral Sentiment: Mizuho increased its price target from $264 to $295 but retained a “neutral” rating. The limited implied upside suggests the firm views much of the favorable Investor Day news as already reflected in CRL’s elevated share price. Mizuho price-target update
• Negative Sentiment: A Seeking Alpha analysis argued that the positive Investor Day announcements are “fully priced in,” raising concerns that the stock’s valuation leaves less room for further gains unless Charles River delivers on its long-term targets. Positive Investor Day Is Fully Priced In